About Transcriptional activator protein Pur-alpha
Transcriptional activator protein Pur-alpha (PURA) is a protein
from Homo sapiens identified by UniProt accession
Q00577, 322 residues long.
MolForge cross-references it against 0 known binders and
125 disease associations.
Target properties
| Protein name | Transcriptional activator protein Pur-alpha |
| UniProt accession | Q00577 |
| Gene | PURA |
| Organism | Homo sapiens |
| Length | 322 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (125)
Diseases linked to this target (Open Targets).
- PURA-related severe neonatal hypotonia-seizures-encephalopathy syndrome due to a point mutation · score 0.79
- Intellectual disability · score 0.70
- genetic disorder · score 0.54
- neurodegenerative disease · score 0.53
- Global developmental delay · score 0.52
- Neonatal hypotonia · score 0.52
- Delayed speech and language development · score 0.52
- Seizure · score 0.51
- complex neurodevelopmental disorder · score 0.37
- mathematical ability · score 0.33
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q00577-F1 | alphafold | PREDICTED | 78.16 | — |
Amino-acid sequence (322 residues)
MADRDSGSEQ GGAALGSGGS LGHPGSGSGS GGGGGGGGGG GGSGGGGGGA PGGLQHETQE LASKRVDIQN KRFYLDVKQN AKGRFLKIAE VGAGGNKSRL TLSMSVAVEF RDYLGDFIEH YAQLGPSQPP DLAQAQDEPR RALKSEFLVR ENRKYYMDLK ENQRGRFLRI RQTVNRGPGL GSTQGQTIAL PAQGLIEFRD ALAKLIDDYG VEEEPAELPE GTSLTVDNKR FFFDVGSNKY GVFMRVSEVK PTYRNSITVP YKVWAKFGHT FCKYSEEMKK IQEKQREKRA ACEQLHQQQQ QQQEETAAAT LLLQGEEEGE ED
Explore Transcriptional activator protein Pur-alpha with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets